Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
6 studies found for:    17151364 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Zileuton
2 Recruiting Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib
3 Not yet recruiting Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia - Chronic Phase
Interventions: Drug: Dasatinib 100 MG [Sprycel];   Drug: Nilotinib 150mg oral capsule [Tasigna]
4 Unknown  Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion
Condition: Philadelphia Chromosome-positive Chronic Myelocytic Leukemia
Intervention: Procedure: Stem cell transplantation
5 Completed STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Condition: Leukemia
Interventions: Biological: recombinant interferon alfa;   Drug: cytarabine;   Drug: imatinib mesylate
6 Withdrawn Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention: Drug: IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)

Study has passed its completion date and status has not been verified in more than two years.